KRAS and neoplasm: Lastly, treatment of Kras/Trp53/Stk11-mutant tumours with Axl inhibitors has recently been shown to reverse STK11LOF-driven resistance to PD-1 ICB in mouse models through enhancing type I IFN production by DCs to promote T cell proliferation (Fig. 2) [70].